Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
FAB LMB96: Reduced Intensity Therapy for Mature B-cell Lymphoma/Leukemia
NCT00162656Phase 3Completed
- Sponsor
- Gustave Roussy
- Start
- May 1996
- Primary completion
- May 2004
- Modality
- Small Molecules
- Countries
- 3
01
Overview
Phase 3, randomised, open-label trial of cyclophosphamide, cytarabine and etoposide in mature B-cell lymphoma, Burkitt lymphoma (BL), diffuse large B-cell lymphoma (DLBCL) and 1 more (6 arms), sponsored by Gustave Roussy. Primary endpoint: Event Free Survival at 3 years. Started May 1996; status: completed.
02
Drugs
cyclophosphamidecytarabineetoposide
03
Conditions
mature B-cell lymphomaBurkitt lymphoma (BL)diffuse large B-cell lymphoma (DLBCL)B cell acute lymphoblastic leukemia (B-ALL)
Beyond the preview
Go deeper on NCT00162656.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00162656.